Carlyle Group Funds Fight Of Lou Gehrig’s Disease

WASHINGTON (AP) — Bloomberg LP CEO Daniel Doctoroff is joining with New York City Mayor Michael Bloomberg and David Rubenstein of Washington-based private equity firm The Carlyle Group to fund a $25 million initiative for treatment of Lou Gehrig’s disease.

They announced the three-year initiative called Target ALS on Thursday to provide a new system for sharing and coordinating findings among researchers. It will be managed by researchers at Columbia University Medical Center.

Target ALS is the next phase of a research initiative of New York-based Project A.L.S. and the Packard Center for ALS Research at Johns Hopkins University in Baltimore.

Researchers say the short-term goal is to facilitate drug-development programs at pharmaceutical and biotech companies. The longer-term goal is to find effective therapies for the disease.

(Copyright 2013 by The Associated Press. All Rights Reserved.)


Leave a Reply

Fill in your details below or click an icon to log in:

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

More From CBS Baltimore

Track Weather On The Go With Our App!
Your Podcast Network

Listen Live